title: Low-dose Gemtuzumab-Ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study.
authors.forename: Antonella
authors.initials: A
authors.lastname: Poloni
authors.forename: Debora
authors.initials: D
authors.lastname: Capelli
authors.forename: Silvia
authors.initials: S
authors.lastname: Trappolini
authors.forename: Benedetta
authors.initials: B
authors.lastname: Costantini
authors.forename: Mauro
authors.initials: M
authors.lastname: Montanari
authors.forename: Guido
authors.initials: G
authors.lastname: Gini
authors.forename: Ilaria
authors.initials: I
authors.lastname: Scortechini
authors.forename: Giorgia
authors.initials: G
authors.lastname: Mancini
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Discepoli
authors.forename: Pietro
authors.initials: P
authors.lastname: Leoni
authors.forename: Attilio
authors.initials: A
authors.lastname: Olivieri
mesh_terms: D000368:Aged; D000617:Aminoglycosides / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000079982:Gemtuzumab